Sartara (CERT) Q3 2025: Software Revenue Jumps 22% as Tier 1 Services Slowdown Reshapes Outlook
Sartara’s third quarter revealed a sharp divergence between robust software growth and persistent Tier 1 services headwinds, as pharma customer caution pushed bookings below expectations and altered typical seasonality. Strategic R&D investments and new product launches, especially in AI-enabled biosimulation, are sustaining margin strength and positioning the company for a more software-centric future. Management’s guidance signals confidence in continued software momentum, but services volatility and large customer hesitancy will remain key watchpoints into 2026.
Summary
- Software Outpaces Services: Strong software growth and product innovation offset Tier 1 services softness.
- Margin Strength Holds: Profitability outperformed as mix shifted toward higher-margin software and R&D spend rose.
- 2026 Hinges on Services Recovery: Tier 1 customer hesitancy clouds near-term services outlook despite biosimulation adoption tailwinds.
Performance Analysis
Sartara delivered 10% year-over-year revenue growth in Q3, with software revenue up 22%—driven by both organic growth and ChemAxon, discovery informatics acquisition, contribution—while services revenue grew just 3%, reflecting a pronounced slowdown among Tier 1 (large pharma) customers. Software bookings expanded 17% year-over-year, with strength in both Tier 1 and Tier 3 (smaller biotech) segments, though Tier 2 lagged due to timing. In contrast, services bookings declined 9%, as large pharma deferred projects and extended decision timelines, a trend persisting into October and breaking historical Q4 seasonality patterns.
Adjusted EBITDA margin reached 34%, exceeding expectations, as higher software mix and cost discipline offset increased R&D and sales investments. R&D spend rose 24% year-over-year, now at 10% of revenue, underscoring management’s commitment to innovation despite the challenging macro. The ChemAxon business, still largely license-driven, aided gross margin, though it reduced the proportion of recurring (ratable) software revenue.
- Software Mix Drives Margin: Higher-margin software and productivity gains from prior services restructuring lifted gross profit.
- Tier 1 Services Drag: Large pharma customers delayed decisions, pushing bookings and revenue into future quarters.
- R&D Investment Sustained: Sartara maintained elevated R&D spend, fueling new AI and cloud-based product launches.
Trailing 12-month bookings rose 12% year-over-year, but organic bookings excluding ChemAxon declined 4%, highlighting reliance on acquisitions for growth. Share repurchases and a term loan repricing further supported adjusted EPS and future interest expense savings.
Executive Commentary
"Our team remains focused on investing for growth, with R&D up 24% versus the same period a year ago, and increasing to 10% of revenue from 9% in the prior year period. On the other hand, third quarter bookings of $96.6 million came in below our expectations, representing growth of 1%. Among our Tier 1 services customers, we observed cautious spending behavior, with some customers pushing deal timelines later into the fourth quarter and into 2026."
William Curie, Chief Executive Officer
"We do still expect from Q3 into Q4 a sequential increase, but not to the same magnitude that we've seen historically. Historically, you've seen a book to bill in Q4 that's, you know, 1.3 to 1.4, and we don't anticipate that being the case given what we've seen through October."
John Gallagher, Chief Financial Officer
Strategic Positioning
1. Software-Led Margin Expansion
Software’s rising share of total revenue is reshaping Sartara’s profit profile, as recurring and license-based products deliver higher gross margins than services. The ChemAxon acquisition accelerated this shift, though its upfront license revenue temporarily lowers the ratable (subscription) mix. Management is clear that future growth will increasingly depend on software innovation and adoption across both large pharma and biotech customers.
2. R&D and AI-Driven Product Innovation
R&D spending grew 24% year-over-year, reflecting a deliberate prioritization of product development despite macro headwinds. New launches—such as Phoenix Cloud, a cloud-based modeling suite, and Sartara IQ, an AI-powered QSP (quantitative systems pharmacology) platform—are designed to expand biosimulation’s role from clinical to discovery and preclinical phases. Early customer feedback is positive, and management expects these innovations to drive both adoption and efficiency gains.
3. Services Volatility and Customer Segmentation
Tier 1 services bookings remain the primary drag, with large pharma clients delaying spend and extending project timelines. In contrast, Tier 3 (smaller biotech) services saw double-digit growth, partially offsetting the Tier 1 softness. Management notes that Tier 1 caution is linked to macro uncertainty and ongoing R&D allocation reviews, rather than a structural decline in biosimulation demand.
4. Regulatory Services Under Review
The regulatory services segment faces inconsistent performance, prompting an ongoing strategic review. While this business generates cash to fund growth and buybacks, management is weighing alternatives and expects to announce a decision before year-end. This move could further concentrate Sartara’s focus on higher-growth, higher-margin software and technology-enabled services.
5. Capital Allocation and Shareholder Returns
Sartara repurchased $41 million in stock year-to-date and executed a term loan repricing to reduce future interest expense. These actions, combined with disciplined expense management, support adjusted EPS growth even as organic bookings remain pressured.
Key Considerations
Sartara’s Q3 highlights a business model in transition, with software and biosimulation adoption offsetting services volatility. Strategic execution and capital allocation are supporting near-term profitability, but the path to sustained growth depends on customer budget normalization and continued innovation uptake.
Key Considerations:
- Software Growth Engines: SimCYP, ChemAxon, and Phoenix Cloud are driving software bookings and margin leverage.
- Tier 1 Customer Hesitancy: Large pharma delays are muting services growth and clouding near-term visibility.
- AI and Platform Differentiation: Sartara IQ and embedded AI features are expanding use cases and customer efficiency.
- Regulatory Services Uncertainty: The outcome of the strategic review could reshape the company’s cash flow profile and segment focus.
- Capital Returns and Balance Sheet: Share repurchases and debt repricing bolster EPS and financial flexibility.
Risks
Continued Tier 1 services weakness, prolonged pharma budget caution, and regulatory or macro disruptions could further pressure bookings and revenue. The outcome of the regulatory services review introduces execution risk, while the shift toward license-heavy software may impact recurring revenue visibility. Integration of acquired businesses and successful scaling of new AI-driven products remain critical execution watchpoints.
Forward Outlook
For Q4 2025, Sartara expects:
- Sequential increase in bookings, but below typical Q4 seasonality due to persistent Tier 1 delays.
- Continued margin strength as software mix rises and R&D investments remain elevated.
For full-year 2025, management narrowed guidance:
- Revenue of $415 to $420 million (8% to 9% growth).
- Adjusted EBITDA margin at the high end, around 32%.
- Adjusted EPS of $0.45 to $0.47.
Management highlighted:
- Persistent Tier 1 services caution, with bookings delays extending into Q4 and 2026.
- Positive biosimulation adoption trends and strong software pipeline positioning for 2026.
Takeaways
Sartara’s Q3 underscores a business model pivot toward software and biosimulation innovation, with margin resilience and R&D intensity offsetting services headwinds. The company’s ability to drive adoption of new AI-enabled platforms and navigate large customer caution will define its growth trajectory into 2026.
- Software Momentum: Robust product launches and ChemAxon integration are fueling top-line and margin gains despite services volatility.
- Tier 1 Services Remain a Drag: Large pharma hesitancy is breaking seasonal patterns and setting a lower base for 2026 services growth.
- Investor Focus Forward: Watch for stabilization in Tier 1 budgets and evidence that new software offerings can accelerate both adoption and recurring revenue mix.
Conclusion
Sartara’s Q3 2025 results highlight a decisive shift toward higher-margin software and biosimulation innovation, even as Tier 1 services uncertainty tempers near-term growth. Sustained R&D investment and successful new product uptake will be critical to maintaining momentum and navigating sector volatility into next year.
Industry Read-Through
Sartara’s quarter signals a broader industry pivot toward software-driven biosimulation and AI-enabled modeling, as life sciences customers seek efficiency and regulatory alignment amid budget caution. The pronounced Tier 1 services slowdown reflects pharma’s ongoing macro risk aversion, a trend likely to affect contract research and technology providers across the sector. Companies with differentiated platforms, recurring revenue models, and deep R&D pipelines are best positioned to capture the next wave of drug development spend as the market stabilizes. Watch for further consolidation and strategic reviews among service-heavy players as the industry recalibrates around software and data-driven value propositions.